Legal Representation
Attorney
John Paul Oleksiuk
USPTO Deadlines
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 22, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Sep 22, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 29, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 28, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jan 22, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jan 22, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 16, 2024 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Dec 16, 2024 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Dec 16, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 16, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 22, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 18, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 23, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Aug 19, 2024 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Aug 19, 2024 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Aug 14, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 14, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Feb 9, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 8, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 8, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 8, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 12, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 10, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 10, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 10, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 10, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 8, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 8, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 8, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 16, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 21, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 21, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 1, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 26, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 26, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 26, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 28, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 28, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 28, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 27, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 28, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 26, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders
Class 044
Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
Classification
International Classes
005
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CRISPR"